Novel therapeutic strategies for rare mutations in non-small cell lung cancer

作者全名：Gou, Qitao; Gou, Qiheng; Gan, Xiaochuan; Xie, Yuxin

作者地址：[Gou, Qitao; Gou, Qiheng] Sichuan Univ, West China Hosp, Canc Ctr, Dept Radiat Oncol, Chengdu, Peoples R China; [Gou, Qitao; Gou, Qiheng] Sichuan Univ, West China Hosp, Canc Ctr, Dept Head & Neck Oncol, Chengdu, Peoples R China; [Gan, Xiaochuan] Chongqing Med Univ, Affiliated Hosp 1, Dept Oncol, Chongqing, Peoples R China; [Xie, Yuxin] Sichuan Univ, West China Hosp, Canc Ctr, Dept Med Oncol, Chengdu, Peoples R China

通信作者：Gou, QH (通讯作者)，Sichuan Univ, West China Hosp, Canc Ctr, Dept Radiat Oncol, Chengdu, Peoples R China.; Gou, QH (通讯作者)，Sichuan Univ, West China Hosp, Canc Ctr, Dept Head & Neck Oncol, Chengdu, Peoples R China.

来源：SCIENTIFIC REPORTS

ESI学科分类：Multidisciplinary

WOS号：WOS:001214241900015

JCR分区：Q1

影响因子：3.8

年份：2024

卷号：14

期号：1

开始页：　

结束页：　

文献类型：Article

关键词：Non-small cell lung cancer; Target therapy; Oncologic driver; Rare mutations

摘要：Lung cancer is still the leading cause of cancer-related mortality. Over the past two decades, the management of non-small cell lung cancer (NSCLC) has undergone a significant revolution. Since the first identification of activating mutations in the epidermal growth factor receptor (EGFR) gene in 2004, several genetic aberrations, such as anaplastic lymphoma kinase rearrangements (ALK), neurotrophic tropomyosin receptor kinase (NTRK) and hepatocyte growth factor receptor (MET), have been found. With the development of gene sequencing technology, the development of targeted drugs for rare mutations, such as multikinase inhibitors, has provided new strategies for treating lung cancer patients with rare mutations. Patients who harbor this type of oncologic driver might acquire a greater survival benefit from the use of targeted therapy than from the use of chemotherapy and immunotherapy. To date, more new agents and regimens can achieve satisfactory results in patients with NSCLC. In this review, we focus on recent advances and highlight the new approval of molecular targeted therapy for NSCLC patients with rare oncologic drivers.

基金机构：Sichuan University Education Foundation

基金资助正文：No Statement Available